Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review
dc.contributor.author | Akl, Elie A. | |
dc.contributor.author | Briel, Matthias | |
dc.contributor.author | You, John J. | |
dc.contributor.author | Sun, Xin | |
dc.contributor.author | Johnston, Bradley C. | |
dc.contributor.author | Busse, Jason W. | |
dc.contributor.author | Mulla, Sohail | |
dc.contributor.author | Lamontagne, Francois | |
dc.contributor.author | Bassler, Dirk | |
dc.contributor.author | Vera, Claudio | |
dc.contributor.author | Alshurafa, Mohamad | |
dc.contributor.author | Katsios, Christina M. | |
dc.contributor.author | Zhou, Qi | |
dc.contributor.author | Cukierman Yaffe, Tali | |
dc.contributor.author | Gangji, Azim | |
dc.contributor.author | Mills, Edward J. | |
dc.contributor.author | Walter, Stephen D. | |
dc.contributor.author | Cook, Deborah J. | |
dc.contributor.author | Schuenemann, Holger J. | |
dc.contributor.author | Altman, Douglas G. | |
dc.contributor.author | Guyatt, Gordon H. | |
dc.date.accessioned | 2024-01-10T13:16:26Z | |
dc.date.available | 2024-01-10T13:16:26Z | |
dc.date.issued | 2012 | |
dc.description.abstract | Objective To assess the reporting, extent, and handling of loss to follow-up and its potential impact on the estimates of the effect of treatment in randomised controlled trials. | |
dc.description.abstract | Design Systematic review. We calculated the percentage of trials for which the relative risk would no longer be significant under a number of assumptions about the outcomes of participants lost to follow-up. | |
dc.description.abstract | Data sources Medline search of five top general medical journals, 2005-07. | |
dc.description.abstract | Eligibility criteria Randomised controlled trials that reported a significant binary primary patient important outcome. | |
dc.description.abstract | Results Of the 235 eligible reports identified, 31 (13%) did not report whether or not loss to follow-up occurred. In reports that did give the relevant information, the median percentage of participants lost to follow-up was 6% (interquartile range 2-14%). The method by which loss to follow-up was handled was unclear in 37 studies (19%); the most commonly used method was survival analysis (66, 35%). When we varied assumptions about loss to follow-up, results of 19% of trials were no longer significant if we assumed no participants lost to follow-up had the event of interest, 17% if we assumed that all participants lost to follow-up had the event, and 58% if we assumed a worst case scenario (all participants lost to follow-up in the treatment group and none of those in the control group had the event). Under more plausible assumptions, in which the incidence of events in those lost to follow-up relative to those followed-up is higher in the intervention than control group, results of 0% to 33% trials were no longer significant. | |
dc.description.abstract | Conclusion Plausible assumptions regarding outcomes of patients lost to follow-up could change the interpretation of results of randomised controlled trials published in top medical journals. | |
dc.description.funder | Pfizer | |
dc.description.funder | Swiss National Foundation | |
dc.description.funder | Roche Research Foundation | |
dc.description.funder | Ontario Ministry of Health and Long-Term Care | |
dc.description.funder | National Natural Science Foundation of China | |
dc.description.funder | SickKids Foundation | |
dc.description.funder | CIHR | |
dc.description.funder | Canadian Chiropractic Research Foundation | |
dc.description.funder | Kidney Foundation of Canada/Canadian Society of Nephrology | |
dc.description.funder | Cancer Research UK | |
dc.fechaingreso.objetodigital | 2024-05-06 | |
dc.format.extent | 12 páginas | |
dc.fuente.origen | WOS | |
dc.identifier.doi | 10.1136/bmj.e2809 | |
dc.identifier.issn | 1756-1833 | |
dc.identifier.pubmedid | MEDLINE:22611167 | |
dc.identifier.uri | https://doi.org/10.1136/bmj.e2809 | |
dc.identifier.uri | https://repositorio.uc.cl/handle/11534/78585 | |
dc.identifier.wosid | WOS:000304359600008 | |
dc.information.autoruc | Medicina;Vera C ;S/I;687 | |
dc.language.iso | en | |
dc.nota.acceso | contenido completo | |
dc.publisher | BMJ PUBLISHING GROUP | |
dc.revista | BMJ-BRITISH MEDICAL JOURNAL | |
dc.rights | acceso abierto | |
dc.subject | INTENTION-TO-TREAT | |
dc.subject | ANTIRETROVIRAL TREATMENT | |
dc.subject | METHODOLOGICAL QUALITY | |
dc.subject | MISSING-DATA | |
dc.subject | PROGRAMS | |
dc.subject | OUTCOMES | |
dc.subject | BIAS | |
dc.subject | METAANALYSIS | |
dc.subject.ods | 03 Good Health and Well-being | |
dc.subject.odspa | 03 Salud y bienestar | |
dc.title | Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review | |
dc.type | artículo | |
dc.volumen | 344 | |
sipa.codpersvinculados | 687 | |
sipa.index | WOS | |
sipa.index | Scopus | |
sipa.trazabilidad | Carga SIPA;09-01-2024 |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT)- systematic review.pdf
- Size:
- 329.38 KB
- Format:
- Adobe Portable Document Format
- Description: